Classification of acute lymphoblastic and myeloid leukemias (ALL and AML) remains 35 heavily based on phenotypic resemblance to normal hematopoietic precursors. This 36 framework can provide diagnostic challenges for immunophenotypically heterogeneous 37 immature leukemias, and ignores recent advances in understanding of developmental 38 multipotency of diverse normal hematopoietic progenitor populations that are 39 identified by transcriptional signatures. We performed transcriptional analyses of a 40 large series of acute myeloid and lymphoid leukemias and detected significant overlap 41 in gene expression between cases in different diagnostic categories. Bioinformatic 42 classification of leukemias along a continuum of hematopoietic differentiation identified 43 leukemias at the myeloid/T-lymphoid interface, which shared gene expression 44 programs with a series of multi or oligopotent hematopoietic progenitor populations, 45 including the most immature CD34+CD1a-CD7-subset of early thymic precursors.
) derived from datasets 147 generated here or publicly available (19, 23, 24, (34) (35) (36) . When specific genesets were 148 derived from published data, differential expression analysis was performed as 149 indicated above using the contrasts indicated in Table S1 . Differentially expressed genes 186 We next examined the transcriptional differences between AML-like cases and the rest 187 of the T-ALL cohort. 2274 genes ( Supplementary Table S3 ) were significantly 188 differentially expressed between the two groups (FDR <0.05), with 1213 and 1061 189 respectively upregulated and downregulated in AML-like T-ALLs. Pathway analysis 190 revealed that AML-like T-ALLs had elevated expression of genes involved in cell cycle 191 and mitochondrial, amino-acid and pyruvate metabolism, and high levels of interferon-192 related genes, MYC, HOXA, MEIS1 and GATA2 targets ( Figure 1B) . Gene-sets that were 193 previously reported to be upregulated in AML in independent datasets were also 194 significantly over-represented. In contrast, TCR, NOTCH1 and TNF signaling were all 195 downregulated.
AML-like T-ALL is enriched for myeloid progenitor transcriptional signatures

196
We then sought to better characterize AML-like T-ALLs similarity to normal stem and 197 progenitor cells, by performing GSEA using normal umbilical cord blood (UCB)
198
hematopoietic progenitor transcriptional signatures that we previously reported (38).
199
AML-like T-ALLs were significantly enriched for megakaryocytic-erythroid progenitor
200
(MEP) and granulocyte-monocyte progenitor (GMP), but not hematopoietic stem cells 201 (HSC) signatures. These leukemias were also enriched for a GMP signature from an 202 independent data-set (23), and resembled lymphoid-mono-dendritic progenitors 203 (LMDP) from an UCB-derived humanized murine model of early lymphoid development 204 (24) ( Figure 1C ). To confirm transcriptional similarity to myeloid progenitors, we 205 combined the gene expression of the T-ALL samples with that of highly purified stem 206 and progenitor populations (38) on a 2D PCA map. Consistent with the GSEA results,
207
AML-like T-ALLs localized in the HSPC differentiation space, near GMPs ( Figure 1D ). Figure S2A ).
215
The genes most differentially expressed in each subpopulation (Supplementary Figure   216 S2B and Supplementary Table S4 ) were consistent with known T-lymphopoietic 217 transcriptional patterns. PCA also reflected this developmental progression 218 (Supplementary Figure S2C ), which was similar to an in-vitro system of human 219 thymocyte differentiation from UCB CD34+ cells (39) (Supplementary Figure S2D ).
220
PCA identified 3 main clusters: a rare (Supplementary Figure S2A) GSEAs to assess the transcriptional similarity of AML-like T-ALLs to normal thymocyte 226 subsets. Strikingly, AML-like T-ALLs were strongly positively enriched for genes that 227 were specifically expressed by the most immature CD34+CD1a-CD7-thymic 228 subpopulation ( Figure 1C ). Of note, this signature differed from an ETP transcriptional 229 profile that we previously reported, which was derived by comparison to CB stem and the rest of the T-ALL cohort, AML-like T-ALL samples were negatively enriched for 'late' thymic discriminating genes ( Figure 1C ). Taken together, these results indicate that 233 AML-like T-ALLs share gene expression programs with both UCB-derived myeloid-234 competent progenitors and the most immature thymic precursors, which also retain 235 myeloid differentiation potential (27).
236
Iterative Clustering and Guide Gene Selection analysis identifies a continuum of
237 leukemic differentiation arrest 238 The recently described ICGS method employs serial iterative clustering with pattern-239 specific guide genes to define coherent transcriptional patterns between samples and 240 then groups these samples into cellular states that recapitulate developmental 241 trajectories (31). We reasoned this method could help resolve stages of differentiation 242 arrest in leukemia. To test the feasibility of applying this approach to leukemic datasets, 243 we initially used ICGS to analyze two published series of adult (33) and pediatric ( Supplementary Table S5 ), and 247 ordered the T-ALL samples in clusters along a continuum of expression of these genes.
248
Along this spectrum, adult T-ALLs attributed to ICGS clusters with the lowest expression 249 of thymic-associated genes (Groups A and B), but with high expression of HSPC and 250 myeloid genes, were enriched for the ETP-ALL immunophenotype (10, (12) (13) (14) . For the 251 pediatric cohort (32), ICGS ordering recapitulated in an unsupervised manner the 252 classification the authors had derived linking mutations to thymic developmental stages 253 (Supplementary Figure S3C and S3D). We thus concluded that ICGS allows unbiased 254 classification of leukemic samples according to their stage of differentiation arrest.
12
We then used ICGS to analyze our patient cohort. ICGS classified these leukemias into 256 five developmental clusters that were defined by the levels of expression of a limited 257 number of guide genes (Figure 2A and Supplementary Table S5 ) that again 258 predominantly comprised transcripts that discriminate hematopoietic cell types. The Mutational analysis of ICGS-defined clusters 277 We performed targeted next generation sequencing (NGS) of the 79/124 cases (34 T-
278
ALLs and 45 AMLs) where diagnostic material was available. The NGS panel
13
( Supplementary Table S6 ) had a predominance of genes that are more often altered in 280 T-ALL, including mutations typically found in the immature subgroup that overlap with 281 those seen in AML (9, 10, 12, 40) . Comprehensive results are in Supplementary Table   282 S7, and all mutations detected in ≥ 2 patients are shown in Figure 2C . Figure 3C) . These data suggest that interface AMLs demonstrate significant lymphoid 330 orientation, which can be more pronounced than the T-ALLs with which they co-cluster interface AMLs ( Figure 3D ). 335 Further GSEA revealed that interface Cluster 2 was significantly enriched for a myeloid appears to be driven by interface AMLs rather than T-ALLs.
334
ICGS-defined interface AMLs transcriptionally resemble mixed phenotype leukemia
350
Interface AMLs have poor outcomes 351 The fact that interface AMLs exhibit markedly different transcription to other AML cases 352 led us to speculate that these leukemias may have specific biology which in turn might 353 affect clinical behavior. We therefore evaluated the outcome of interface AMLs in two 354 independent studies (45, 46) . To identify these cases, we calculated an interface AML
355
(IAL) score based on gene expression differences between interface and non-interface 356 AMLs in our cohort (Supplementary Methods and Table S8 ). Outcome analyses revealed 357 that AMLs with high IAL scores had significantly shorter survival in both studies
358
( Figures 4A and 4B) . Within the ALFA-1701 group, we found that high IAL scores 359 predicted lack of response to gemtuzumab ozogamicin ( Figure 4C ), which in keeping 360 with our previous results (47), correlated with reduced expression of CD33 in high IAL 361 cases ( Figure 4D ). Importantly, multivariate analysis of the ALFA-0701 cohort (46) 362 revealed that IAL score predicted outcome independently of other prognostic variables, 363 including cytogenetic classification and the recently described LSC17 score (34) ( Table   364 1). Consistent with this, our IAL signature had almost no overlap with the LSC17 365 signature, or the extended 48 gene signature that was reported in the same paper (34)
366
(Supplementary Figure S4A and S4B ). Full comparison of clinicobiological and 367 mutational profiles of ALFA-0701 patients with high and low IAL scores is shown in 368 Supplementary Table S9 . Finally, we evaluated whether IAL High cases had evidence of 369 lymphoid transcriptional activation. In keeping with our earlier results (Figure 3) , we 370 found that IAL High cases in both AML cohorts were significantly enriched for both MLP 371 signatures and B-lymphoid gene expression ( Supplementary Figure S4C-S4G ).
Discussion: 373
In keeping with modern concepts of a hematopoietic progenitor framework that (48). Overall, these results suggest that these leukemias may be more likely to arise 385 from lymphoid-oriented progenitors and/or be arrested at an early stage of lymphoid 386 orientation (prior to CD19 expression) than is currently recognized.
387
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